FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...
The approval is based on the results of Corcept’s Phase 3 ROSELLA trial, which showed improvements in both progression-free ...
Corcept (CORT) stock jumped 40% as FDA approved Lifyorli for platinum-resistant ovarian cancer, completing review 2.5 months ...
The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for the treatment of adults with ...
Corcept Therapeutics recently received U.S. FDA approval for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary ...
FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to ...
Corcept Therapeutics (NASDAQ:CORT) shares surged 40% Wednesday after the Food and Drug Administration approved relacorilant ...
The FDA has approved relacorilant (Lifyorli, Corcept Therapeutics) in combination with nab-paclitaxel for adults with ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...
Pharmaceutical Technology on MSN
Corcept’s first-in-class ovarian cancer drug gains FDA approval
The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and ...
InvestorsHub on MSN
Corcept shares soar after FDA approves relacorilant cancer treatment
Shares of Corcept Therapeutics (NASDAQ:CORT) surged about 40% on Wednesday after the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results